WEKO3
アイテム
{"_buckets": {"deposit": "7e7676cd-3f92-4798-92ed-7df0c7e559fd"}, "_deposit": {"created_by": 2, "id": "387", "owners": [2], "pid": {"revision_id": 0, "type": "depid", "value": "387"}, "status": "published"}, "_oai": {"id": "oai:nagasaki-u.repo.nii.ac.jp:00000387", "sets": ["9"]}, "author_link": ["1981", "1976", "1972", "1979", "1973", "1980", "1982", "1984", "1971", "1983", "1985", "1975", "1986", "1977", "1987", "1974", "1970", "1978"], "item_2_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2019-11-10", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "11", "bibliographicPageStart": "1769", "bibliographicVolumeNumber": "11", "bibliographic_titles": [{"bibliographic_title": "Cancers"}]}]}, "item_2_description_4": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Background: Lenvatinib is currently available as the first-line treatment for advanced unresectable hepatocellular carcinoma. We evaluated the relationship between its relative dose intensity (RDI) and response in clinical settings. Methods: From March 2018 to May 2019, 93 patients were administered lenvatinib at the Nagasaki University Hospital and its related facilities. Among these, 81 patients (66 men, 15 women, median age 72.0) who received lenvatinib were analyzed retrospectively. Results: Fourteen patients were Child?Pugh grade B, and 15 had received other systemic therapy. According to Response Evaluation Criteria in Solid Tumors (RECIST), the objective response (OR) rate was 17.3%. The overall survival (OS) was significantly better in the OR group (p = 0.011). There was a significant difference in RDI between the OR and non-OR groups (p \u003c 0.05). The area under the receiver operating characteristics curve for OR prediction by the 4, 8, 12, and 16-week RDI were 0.666, 0.747, 0.731, and 0.704, respectively. In the 8-week RDI ?67.0% group, OS was significantly better than in the 8-week RDI\u003c 67.0% group (p = 0.003). Conclusions: Because a sufficient RDI is required to achieve an OR, it is strongly recommended that lenvatinib should be administered to patients with good hepatic function and status.", "subitem_description_type": "Abstract"}]}, "item_2_description_63": {"attribute_name": "引用", "attribute_value_mlt": [{"subitem_description": "Cancers, 11(11), art.no.1769; 2019", "subitem_description_type": "Other"}]}, "item_2_publisher_33": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "MDPI"}]}, "item_2_relation_12": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_type": "isIdenticalTo", "subitem_relation_type_id": {"subitem_relation_type_id_text": "10.3390/cancers11111769", "subitem_relation_type_select": "DOI"}}]}, "item_2_rights_13": {"attribute_name": "権利", "attribute_value_mlt": [{"subitem_rights": "c 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/)."}]}, "item_2_source_id_8": {"attribute_name": "EISSN", "attribute_value_mlt": [{"subitem_source_identifier": "20726694", "subitem_source_identifier_type": "ISSN"}]}, "item_2_version_type_16": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_970fb48d4fbd8a85", "subitem_version_type": "VoR"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Sasaki, Ryu"}], "nameIdentifiers": [{"nameIdentifier": "1970", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Fukushima, Masanori"}], "nameIdentifiers": [{"nameIdentifier": "1971", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Haraguchi, Masafumi"}], "nameIdentifiers": [{"nameIdentifier": "1972", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Miuma, Satoshi"}], "nameIdentifiers": [{"nameIdentifier": "1973", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Miyaaki, Hisamitsu"}], "nameIdentifiers": [{"nameIdentifier": "1974", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Hidaka, Masaaki"}], "nameIdentifiers": [{"nameIdentifier": "1975", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Eguchi, Susumu"}], "nameIdentifiers": [{"nameIdentifier": "1976", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Matsuo, Satoshi"}], "nameIdentifiers": [{"nameIdentifier": "1977", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Tajima, Kazuaki"}], "nameIdentifiers": [{"nameIdentifier": "1978", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Matsuzaki, Toshihisa"}], "nameIdentifiers": [{"nameIdentifier": "1979", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Hashimoto, Satsuki"}], "nameIdentifiers": [{"nameIdentifier": "1980", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ooba, Kazuo"}], "nameIdentifiers": [{"nameIdentifier": "1981", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kugiyama, Yuki"}], "nameIdentifiers": [{"nameIdentifier": "1982", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Yatsuhashi, Hiroshi"}], "nameIdentifiers": [{"nameIdentifier": "1983", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Motoyoshi, Yasuhide"}], "nameIdentifiers": [{"nameIdentifier": "1984", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Shigeno, Masaya"}], "nameIdentifiers": [{"nameIdentifier": "1985", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kinoshita, Noboru"}], "nameIdentifiers": [{"nameIdentifier": "1986", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Nakao, Kazuhiko"}], "nameIdentifiers": [{"nameIdentifier": "1987", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2020-12-18"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "Cancers11_1769.pdf", "filesize": [{"value": "1.9 MB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 1900000.0, "url": {"label": "Cancers11_1769.pdf", "url": "https://nagasaki-u.repo.nii.ac.jp/record/387/files/Cancers11_1769.pdf"}, "version_id": "411f984e-8300-4503-81b2-4c9caa15a17d"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "hepatocellular carcinoma", "subitem_subject_scheme": "Other"}, {"subitem_subject": "lenvatinib", "subitem_subject_scheme": "Other"}, {"subitem_subject": "relative dose intensity", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Response to Lenvatinib Is Associated with Optimal RelativeDose Intensity in Hepatocellular Carcinoma: Experience in Clinical Settings", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Response to Lenvatinib Is Associated with Optimal RelativeDose Intensity in Hepatocellular Carcinoma: Experience in Clinical Settings"}]}, "item_type_id": "2", "owner": "2", "path": ["9"], "permalink_uri": "http://hdl.handle.net/10069/39551", "pubdate": {"attribute_name": "公開日", "attribute_value": "2019-11-20"}, "publish_date": "2019-11-20", "publish_status": "0", "recid": "387", "relation": {}, "relation_version_is_last": true, "title": ["Response to Lenvatinib Is Associated with Optimal RelativeDose Intensity in Hepatocellular Carcinoma: Experience in Clinical Settings"], "weko_shared_id": -1}
Response to Lenvatinib Is Associated with Optimal RelativeDose Intensity in Hepatocellular Carcinoma: Experience in Clinical Settings
http://hdl.handle.net/10069/39551
http://hdl.handle.net/10069/395513d672b5e-e2c0-4466-94f9-4091f6795970
名前 / ファイル | ライセンス | アクション |
---|---|---|
Cancers11_1769.pdf (1.9 MB)
|
|
Item type | 学術雑誌論文 / Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2019-11-20 | |||||
タイトル | ||||||
タイトル | Response to Lenvatinib Is Associated with Optimal RelativeDose Intensity in Hepatocellular Carcinoma: Experience in Clinical Settings | |||||
言語 | ||||||
言語 | eng | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | hepatocellular carcinoma | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | lenvatinib | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | relative dose intensity | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | journal article | |||||
著者 |
Sasaki, Ryu
× Sasaki, Ryu× Fukushima, Masanori× Haraguchi, Masafumi× Miuma, Satoshi× Miyaaki, Hisamitsu× Hidaka, Masaaki× Eguchi, Susumu× Matsuo, Satoshi× Tajima, Kazuaki× Matsuzaki, Toshihisa× Hashimoto, Satsuki× Ooba, Kazuo× Kugiyama, Yuki× Yatsuhashi, Hiroshi× Motoyoshi, Yasuhide× Shigeno, Masaya× Kinoshita, Noboru× Nakao, Kazuhiko |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | Background: Lenvatinib is currently available as the first-line treatment for advanced unresectable hepatocellular carcinoma. We evaluated the relationship between its relative dose intensity (RDI) and response in clinical settings. Methods: From March 2018 to May 2019, 93 patients were administered lenvatinib at the Nagasaki University Hospital and its related facilities. Among these, 81 patients (66 men, 15 women, median age 72.0) who received lenvatinib were analyzed retrospectively. Results: Fourteen patients were Child?Pugh grade B, and 15 had received other systemic therapy. According to Response Evaluation Criteria in Solid Tumors (RECIST), the objective response (OR) rate was 17.3%. The overall survival (OS) was significantly better in the OR group (p = 0.011). There was a significant difference in RDI between the OR and non-OR groups (p < 0.05). The area under the receiver operating characteristics curve for OR prediction by the 4, 8, 12, and 16-week RDI were 0.666, 0.747, 0.731, and 0.704, respectively. In the 8-week RDI ?67.0% group, OS was significantly better than in the 8-week RDI< 67.0% group (p = 0.003). Conclusions: Because a sufficient RDI is required to achieve an OR, it is strongly recommended that lenvatinib should be administered to patients with good hepatic function and status. | |||||
書誌情報 |
Cancers 巻 11, 号 11, p. 1769, 発行日 2019-11-10 |
|||||
出版者 | ||||||
出版者 | MDPI | |||||
EISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 20726694 | |||||
DOI | ||||||
関連タイプ | isIdenticalTo | |||||
識別子タイプ | DOI | |||||
関連識別子 | 10.3390/cancers11111769 | |||||
権利 | ||||||
権利情報 | c 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). | |||||
著者版フラグ | ||||||
出版タイプ | VoR | |||||
出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 | |||||
引用 | ||||||
内容記述タイプ | Other | |||||
内容記述 | Cancers, 11(11), art.no.1769; 2019 |